Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.

Abstract

We conducted high-dimensional propensity score-adjusted cohort studies to examine whether thiazolidinedione use with a statin or fibrate was associated with an increased risk of severe hypoglycemia. We found that concomitant therapy with a thiazolidinedione+fibrate was associated with a generally delayed increased risk of severe hypoglycemia.

• Authors: Charles E Leonard, Xu Han, Warren B Bilker, James H Flory, Colleen M Brensinger, David A Flockhart, Joshua J Gagne, Serena Cardillo, Sean Hennessy
• Journal: Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 115 Pg. 60-7 (May 2016) ISSN: 1872-8227 [Electronic] Ireland
• PMID: 27242124 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Hypoglycemic Agents
• Hypolipidemic Agents
• Thiazolidinediones
• Pioglitazone

Topics

• Aged
• Diabetes Mellitus (drug therapy)
• Drug Interactions
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects, therapeutic use)
• Hyperlipidemias (drug therapy)
• Hypoglycemia (chemically induced)
• Hypoglycemic Agents (adverse effects, therapeutic use)
• Hypolipidemic Agents (adverse effects, therapeutic use)
• Male
• Middle Aged
• Pioglitazone
• Retrospective Studies
• Risk
• Thiazolidinediones (adverse effects, therapeutic use)